Program Profile

Prostate Cancer Foundation-Department of Veterans Affairs Partnership: A Model of Public-Private Collaboration to Advance Treatment and Care of Invasive Cancers

Author and Disclosure Information

 

References

Conclusions

The PCF-VA partnership serves as an example of a public-private health partnership pursuing strategic pathways and bold goals to ensure that every eligible veteran has access to precision oncology. These pathways include advocacy on the part of executive leadership, recognizing existing economies of scale, building compelling narratives to maximize funding, creating flexible requirements, and facilitating a robust, resource-rich scientific network. This partnership already has opened doors to future initiatives and continues to adapt to a rapidly changing health landscape. The discussed strategies have the potential to inform future health initiatives and showcase how a systemic approach to eradicating health inequities can greatly benefit underserved communities.

The success of the PCF-VA partnership represents more than just an efficient partnership model. The partnership’s emphasis on veterans, who exemplify service, highlights the extent to which cancer patients sacrifice to contribute to medical research. This service necessitates a service in kind: all health stakeholders share the responsibility to rapidly advance therapies and care, both to honor the patients who have come before, and to meet the needs of patients with treatment resistant forms of the disease urgently awaiting precision breakthroughs and cures.

Pages

Recommended Reading

Are oncologists liable for pandemic-related treatment delays?
Federal Practitioner
‘Long haul’ COVID recovery worse than cancer rehab for some: CDC
Federal Practitioner
Cancer mortality continues to drop in females as breast cancer reversal looms
Federal Practitioner
Metformin use may curb BCC risk
Federal Practitioner
Stop using Neutrogena and Aveeno spray sunscreen, J&J warns
Federal Practitioner
Recent trend: Melanoma mortality declining rapidly
Federal Practitioner
Hematologic cancer increases risk of delivery complications
Federal Practitioner
Many pandemic-driven changes to cancer clinical trials should remain
Federal Practitioner
New investigational helmet device shrinks glioblastoma
Federal Practitioner
Remote 24-hour monitoring improves life for patients on chemo
Federal Practitioner

Related Articles